Sun Tzu: From "research services" to "health medicine", the way to expand the gene sequencing enterprises.

Guide: He led the company to improve the construction of the sequencing platform from one generation to three generations, to achieve the new three-board listing, from scientific research services to health medicine transformation.
2003, he chose to start a business, has set up two enterprises.
now, as the chairman of Shanghai Passenno Biotech Co., Ltd., he led the company to improve the construction of a sequencing platform from one generation to three generations, realize the new three-board listing, complete the transformation from scientific research services to health medicine, successfully set up a medical testing institute, into the National Health Care Big Data (Nanjing) Center ... Recently, the reporter interviewed in the gene sequencing industry, "up-and-coming" boss of the boss of the grandson Of Que.
talkaboutd about 2003, many people's first memory of the pain is SARS: this aggressive atypical pneumonia in China triggered a "white terror", fortunately in effective isolation, group control and other public health measures under the control of the epidemic was successfully lifted.
to win the smoke-free war, scientists traced the source and found that the culprit was a mutated coronavirus, SARS, and successfully cracked the genome sequence of the virus.
this decipherhas has set off a worldwide upsurge in genetic research.
2003, his grandson, Que, who works for Gene Sequencing, saw an opportunity to embark on a new career journey - creating Shanghai Sonny Biotech Co., Ltd., which specializes in a generation sequencing and primer synthesis business.
SARS events largely showed the importance of genetic sequencing, which was the year I chose to start a business.
" interview, Sun Tzu told reporters, "Although this is a big turning point, but with my previous plant genetic background, genetic sequencing work experience, so it is still in my relatively familiar field."
"talk about entrepreneurship: from the first generation to the second generation, according to market demand gene sequencing is the basis for the establishment of "histology" large database and analysis.
as a popular technology in the medical and health industry, gene sequencing market prospects, by the capital.
Since the 1970s, gene sequencing technology has undergone four changes, the most mature and widely used is the second generation sequencing.
Sun Tzu told reporters that when Shanghai Sonny was founded in 2003, the market and the company's mainstream business were all about a generation of sequencing.
2005, Roche developed 454 second-generation sequencing technology, opening up a new pattern of low-cost, high-throughput sequencing.
saw a rapid change in the gene market that he made his second major decision about his career, co-founding Shanghai Passenno Biotech Co., Ltd. in 2011.
" unlike Shanghai Sonny, Pisano's main business revolves around second-generation sequencing.
," sun-daok said.
company adopts the "deep work" model, including genomics, transcriptional histology, microbiome, conventional sequencing and molecular experiments, third-generation sequencing and a series of sequencing platforms to support competitive scientific research services.
at the same time, Pissonno focuses on "clinical medicine and public health", from chronic disease management to tumor precision diagnosis and treatment gradually layout of its product line.
talk about enterprises: from capital to industry, all the way to upgrade 2017, "genetic community big curry" Huada gene successfully listed, foreshadowing a new market reshuffle, but also its completion of basic scientific research services to reproductive health and other life medicine business transformation of a major milestone.
the IPO gives the capital markets a clear sense of the boom in the gene sequencing industry.
": "The current situation is completely different from that of a decade ago.
" when it comes to the bottleneck of entrepreneurship, Sun Tzu feels the deepest is the capital.
recalls that at the beginning of the millennium, China's entrepreneurial resources were relatively limited, while capital markets were not active, which caused a big obstacle to the development of many biotech companies.
" in 2015, we conducted a share restructuring and successfully completed the first round of financing of nearly 50 million yuan.
Sun Tzu-Kui was always impressed by this, "and was able to gain the capital market recognition at a higher valuation, exceeding my expectations."
" On May 4, 2016, Pissonno successfully listed the new three boards and once again completed the upgrade on capital.
in recent years, high-throughput sequencing has been used more and more widely in clinical medicine, including NIPT, tumor early sieve, personalized drug use and other directions have become the competitive point of the layout market of enterprises.
Sun Tzu clearly recognized the changes in the market and led the company into the "fast track of development": in August 2016, obtained a medical practice license, set up a medical examination institute in Qingpu, Shanghai, officially opened a clinical service tour of health medicine; As one of the few high-quality enterprises selected, Nono is in the National Health Care Big Data (Nanjing) Center and has built independent laboratories in Xuhui District, Qingpu District, Nanjing and Qingdao in Shanghai.
talk about the market: from opportunity to challenge, to meet the new pattern with the benefits of national policies, the development of science and technology, gene sequencing in the field of large-scale health application prospects, especially the rapid decline in sequencing costs, contributing to the gene sequencing market. According
to research by BCC Research, a leading international investment consultancy, the global gene sequencing market will reach US$13.8 billion in 2020, with a COMPOUND annual growth rate of 18.7%.
" gene sequencing has a congenital advantage in China, that is, the Chinese mouth is numerous, and with the improvement of living standards, the demand for health is gradually rising.
so gene sequencing has been clinically recognized in recent years and has been gradually applied to major fields.
" Sun Kui expressed great confidence in the gene industry, "I even believe that in the future everyone will be able to access the services associated with gene sequencing."
" he believes that the focus of future gene sequencing will be closely linked to health medicine, but the industry faces two major risks: first, technical regulation, although there are many genetic enterprises at present, but in line with national policy provisions of the limited clinical applications;
talk about planning: thanks to the team, continue to go ahead in the interview, Sun Tzu Que repeatedly mentioned the company's team, very happy to lead a lean, pragmatic, young team.
" thanks to the dedication of its employees, Pisonno was able to list the new three boards in a relatively short period of time and create brand benefits in a competitive environment.
", "He's grateful for that."
January 2018, Pisseno completed the A-plus round of financing and was invested 30 million yuan by the Nanjing Yangzi Co-creation Fund.
"The funds will be focused on the company's product development and channel construction in clinical medicine." "The company's self-developed products focus on the field of cancer, including genetic testing of women-related tumors and colorectal cancer," said
Sun Tzu.
" in leading the company's steady development at the same time, Sun Tzu Kui personal has also been the first Shanghai "entrepreneurial dream star" the most innovative award, "2014 China's economic person of the year" and other honors.
talk about these achievements, he is very modest to think that these are the evaluation and recognition given by others, but also he continues to move forward in a kind of encouragement and motivation.
interview concluded with Mr. Sun, on the issue of "enterprise future development planning", Mr. Sun firmly said that he needed to stick to the "solve d'etat of China's clinical problems".
", "The next step is to move closer to health medicine and develop products that fit Chinese needs for clinical applications.
" in his plan, the construction of the country's largest intestinal microbiome genetic data, the development of tumor early sieve-related products will be the focus of the company's development.
.